



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of)
HUGHES ET AL)
Serial No. 10/016,850)

Filed: December 14, 2001

For: PHARMACEUTICAL CONJUGATES
WITH ENHANCED PHARMACOKINETIC
CHARACTERISTICS

PML 30, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on or before

44

11010

Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

This SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being filed pursuant to 37 CFR 1.97(c) and is accompanied by a certification as specified in 37 CFR 1.97(e).

BEST AVAILABLE COPY

Group Art Unit: 1614

Examiner: Delacroix Muin

CERTIFICATION UNDER 37 CFR 1.97(e)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication (the International Search Report) from a foreign patent office (The European Patent Office) acting as the International Search Authority in a counterpart foreign (PCT) patent application no more than three months prior to the filing of this Supplemental Information Disclosure Statement (a copy of the International Search Report is enclosed).

Respectfully submitted,

rank / Vxa

Attorney for Applicant

Reg. No. 25,612

4 Venture, Suite 300

Irvine, CA 92618 (949) 450-1750

Facsimile (949) 450-1764

FJUxa/ac

						_	<u></u>				t i or i		
Form PTO-14									DOCKET NO: D-3004		APPLN. NO. 1	0/016,	,850
	FORM	IOITAI A NI			SURI		(ATI	ON	APPLICANT: Hughes tal.				
5 2003	7. E.				A I I C				FILING DATE: 12/14/		GROUP ART: 1	1614	
JART	:						U.	S. PATEN	T DOCUMENTS		1.5		
TRACEMARY EXAMINER			DOCUM	ENT NUM	/BER			DATE	NAME	CLASS	SUBCLASS	RUL!	SING DATE
INITIAL						П	\Box					<u> </u>	
<u>_</u>			\vdash		\vdash	\vdash	+	 			R	大	
											MA) TECH CENT	FCE	5/1/1
							\Box	—			MA	¥	11/
											TEO!	06	$\frac{1}{2n_{\Omega_2}}$
								<u> </u>			CENT	<u></u>	
												77 760	0/200
													" ~~ 000
			_	_		F	FORF	EIGN PAT	ENT DOCUMENTS	s			·
EXANINER			DOCUME	ENT NU	MBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	LATION
INITIAL											1	YES	NO
	wo	00/	7	8	3	0	2	12/28/00	International			 	
	1	0	8	8	5	5	8	04/04/01	Europe			 	₩
	 	 '	-	_	—	 	\vdash	 	 				
		 '	<u> </u>	-	 	-	-	 			-	-	
	<u> </u>	لــــا	<u> </u>	<u> </u>	<u> </u>		Щ				<u> </u>	<u> </u>	<u> </u>
	τ——	т—						OTHER D	OCUMENTS				
									eptide as Effective 4603-4609.	∍ lmmunoadju	ıvant in Rab	obits an	ıd
									on Properties, Nuc				
	the Oligonucleotide-Amino-β-cyclodextrins and Adamantane Conjugates", <i>Bioconjugate Chemistry</i> , July/August 1995, Vol. 6, No. 4, pp. 327-331.												
	 	0,,	mo	<u>y, c.</u>	Путь	Igue.	1 100	30, vo c	, NO. 4, pp. c	·331.			
		 											
 	-	-								 			
									-				
		EXAMINER							DATE CONCIDE	EPEN.			
EXAMI	NER .								DATE CONSIDE	eneb.			
EXAMI	VER								DATE CONSIDI	ENLD.	,		